

RECEIVED

MAY 03 2002

TECH CENTER 1600/2900

#11

Sheet 1 of

JUL 24 2002

RECEIVED

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY/DONE BY GNN-014CP	SERIAL NO. 097835,297
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Bluestone, Jeffrey et al.	TECH CENTER 1600/2900
MAY 01 2002		FILING DATE April 12, 2001	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
J.O.	A1	5,807,734	09/98	Diegel et al.	435	252.33	
J.O.	A2	5,962,320	10/99	Robinson	435	366	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
J.O.	A3	WO 99/57266 A2,A3	11/99	PCT			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

10	A4	Connelly, R.J. et al. "Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes" <i>International Immunology</i> 10(12):1863-1872 (1998);
	A5	Gilliland, L.K. et al. "Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments" <i>Tissue Antigens</i> 47:1-20 (1996);
	A6	Griffin, M.D. et al. "Inhibition of Alloantigen-Specific CD8+ T Cell Activation by a Surface-Linked Anti-CTLA-4 Single Chain Antibody" <i>J. Am. Soc. Nephrol.</i> 10:510A, Abstr. A2579 (1999);
	A7	Griffin, M.D. et al. "Comparative Analysis of the CD28 and 4-IBB Co-Stimulatory Pathways Using a Novel Artificial APC System" <i>J. Am. Soc. Nephrol.</i> 10:510A, Abstr. A2580 (1999);
	A8	Griffin, M.D. et al. "Blockade of T Cell Activation Using a Surface-Linked Single-Chain Antibody to CTLA-4 (CD152)" <i>The Journal of Immunology</i> 164:4433-4442 (2000);
	A9	Hayden, M.S. et al. "Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system" <i>Therapeutic Immunology</i> 1:3-15 (1994);
	A10	Hayden, M.S. et al. "Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen" <i>Tissue Antigens</i> 48:242-254 (1996);
	A11	Hayden, M.S. et al. "Antibody engineering" <i>Current Opinion in Immunology</i> 9:201-212 (1997);
	A12	Malde, P. et al. "Reversal of costimulation by cell surface expression of an anti-CD152 single chain antibody" <i>Immunol.</i> 98(suppl.1):17 (1999);
10	A13	Winberg, G. et al. "Surface Expression of CD28 Single Chain Fv for Costimulation by Tumor Cells" <i>Immunologic Reviews</i> 153:210-223 (1996).

RECEIVED

MAY 06 2002

OFFICE OF PETITIONS

Examiner <i>Ivan Dubrovsky</i>	Date Considered <i>09/13/2004</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	